Bullish Moving Averages
14
Bearish Moving Averages
2
Back Stocks profile
Stock analysis tool for investors
Performance
Today’s low
860.00Today’s High
892.0052W low
650.0052W High
1249.00Open Price
887.00Prev. Close
800.8000Volume
4041.00Value
3487383.00Fundamentals
Market Cap
402.50
Price to Earnings
23.20
Price to Book Value
3.30
Dividend Yield
0.10
PE to Growth
0.70
Op Revenue TTM
363.70
Net Profit TTM
17.35
Cash From Operating Activity
-0.44
Return on Equity %
12.86
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
30 Jul, 2024
74.9
Week
78.1
Month
81
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
887.73
PIVOT
First Resistance
900.37
Second Resistance
916.63
Third Resistance
929.27
First Support
871.47
Second Support
858.83
Third Support
842.57
Relative Strength Index
55.97
Money Flow Index
66.86
MACD
1.04
MACD Signal
-1.81
Average True Range
38.11
Average Directional Index
12.09
Rate of Change (21)
1.4
Rate of Change (125)
3.52
Commodity Channel Index
137.7
Williams %R
-16.9
BETA
1 Month
1.54
3 Month
0.84
1 Year
0.85
3 Year
0.28
PRICE CHANGE ANALYSIS
↑ 4.25%
1 Week
Low
High
821.15
904
↓ -1.02%
1 Month
Low
High
786.05
904
↓ -7.65%
3 Months
Low
High
724.95
1024
↑ 3.88%
6 Months
Low
High
650
1054
↓ -21.56%
1 Year
Low
High
650
1249
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 78.81 | 118.03 | 87.01 | 81.99 | 62.05 | 79.80 | 77.96 | 70.32 | 48.42 | 71.85 | 54.23 | 54.76 | 45.25 | |
| Operating Expenses Qtr | 68.33 | 106.87 | 76.49 | 72.38 | 54.44 | 67.54 | 70.65 | 63.53 | 44.55 | 66.45 | 49.88 | 50.68 | 43.66 | |
| Operating Profit Qtr | 9.20 | 11.17 | 10.16 | 9.10 | 6.79 | 12.18 | 7.00 | 5.32 | 3.58 | 3.00 | 3.24 | 3.67 | 1.16 | |
| EBIDT Qtr Cr | 10.48 | 11.17 | 10.52 | 9.61 | 7.61 | 12.26 | 7.31 | 6.80 | 3.87 | 5.40 | 4.36 | 4.08 | 1.59 | |
| Depreciation Qtr | 1.05 | 0.96 | 0.99 | 0.94 | 0.92 | 0.70 | 0.73 | 0.72 | 0.65 | 0.58 | 0.55 | 0.52 | 0.51 | |
| Net Profit Qtr | 4.13 | 5.06 | 4.22 | 3.94 | 2.40 | 3.89 | 3.46 | 3.15 | 0.94 | 2.30 | 1.87 | 1.84 | 0.33 | |
| Basic EPS Qtr | 8.79 | 10.77 | 8.99 | 8.40 | 5.24 | 8.59 | 7.66 | 7.11 | 2.12 | 5.18 | 4.22 | 4.61 | 0.82 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 349.07 | 276.50 | 226.09 | 135.29 | 113.29 | |
| Operating Expenses Annual Cr | 310.17 | 246.90 | 210.66 | 124.75 | 104.50 | |
| Operating Profit Annual | 38.90 | 27.78 | 13.80 | 9.14 | 8.27 | |
| Operating Profit Margin Annual % | 11.14 | 10.05 | 6.10 | 6.76 | 7.30 | |
| Total Expenses Annual Cr | 327.62 | 258.99 | 217.49 | 130.92 | 110.79 | |
| EBIDT Annual Cr | 38.90 | 29.60 | 15.43 | 10.54 | 8.79 | |
| EBIDT Annual margin % | 11.14 | 10.71 | 6.82 | 7.79 | 7.76 | |
| Depreciation | 3.80 | 2.81 | 2.16 | 2.00 | 1.88 | |
| PAT Before ExtraOrdinary Items Annual Cr | 15.62 | 10.81 | 6.34 | 2.01 | 1.90 | |
| Net Profit Annual | 15.62 | 10.81 | 6.34 | 2.01 | 1.90 | |
| Basic EPS Annual | 33.32 | 24.13 | 11.28 | 5.05 | 4.77 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 121.47 | 96.38 | 68.06 | 43.07 | 41.32 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 11.65 | 54.74 | 45.18 | 32.09 | 14.07 | |
| Total Current Liabilities Annual Cr | 174.47 | 106.17 | 73.75 | 86.46 | 77.78 | |
| Total Capital Plus Liabilities Annual Cr | 307.60 | 257.28 | 186.99 | 161.62 | 133.16 | |
| Fixed Assets Annual | 46.57 | 38.93 | 32.34 | 30.35 | 30.97 | |
| Total Non Current Assets Annual | 50.40 | 41.07 | 34.34 | 31.54 | 32.05 | |
| Total Current Assets Annual | 257.20 | 216.21 | 152.65 | 130.08 | 101.11 | |
| Total Assets Annual | 307.60 | 257.28 | 186.99 | 161.62 | 133.16 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | -0.44 | -14.41 | -2.38 | 0.17 | -10.61 | |
| Cash from Investing Activity Annual | -7.64 | -9.40 | -4.13 | -1.39 | -1.49 | |
| Cash from Financing Annual Activity | 5.99 | 25.18 | 7.47 | -0.71 | 13.70 | |
| Net Cash Flow Annual | -2.08 | 1.36 | 0.96 | -1.93 | 1.59 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 258.49 | 212.64 | 153.54 | 107.95 | 103.57 | |
| ROE Annual % | 12.86 | 11.21 | 9.30 | 4.67 | 4.60 | |
| ROCE Annual % | 26.36 | 17.72 | 11.71 | 11.35 | 12.47 | |
| Total Debt to Total Equity Annual | 0.87 | 0.90 | 0.78 | 0.92 | 0.84 | |
| EBDIT Annual Margin % | 11.14 | 10.77 | 6.87 | 7.86 | 7.79 |
| Indicator | Graph |
|---|---|
| Total Qtr Revenue cr | |
| Operating Expenses Qtr | |
| Operating Profit Qtr | |
| EBIDT Qtr Cr | |
| Depreciation Qtr | |
| Net Profit Qtr | |
| Basic EPS Qtr |
| Indicator | Graph |
|---|---|
| Total Revenue Annual | |
| Operating Expenses Annual Cr | |
| Operating Profit Annual | |
| Operating Profit Margin Annual % | |
| Total Expenses Annual Cr | |
| EBIDT Annual Cr | |
| EBIDT Annual margin % | |
| Depreciation | |
| PAT Before ExtraOrdinary Items Annual Cr | |
| Net Profit Annual | |
| Basic EPS Annual |
| Indicator | Graph |
|---|---|
| Total ShareHolders Funds Annual | |
| Minority Interest Liability Annual Cr | |
| Total Non Current Liabilities Annual Cr | |
| Total Current Liabilities Annual Cr | |
| Total Capital Plus Liabilities Annual Cr | |
| Fixed Assets Annual | |
| Total Non Current Assets Annual | |
| Total Current Assets Annual | |
| Total Assets Annual | |
| Contingent Liabilities plus Commitments Annual Cr |
| Indicator | Graph |
|---|---|
| Cash from Operating Activity Annual | |
| Cash from Investing Activity Annual | |
| Cash from Financing Annual Activity | |
| Net Cash Flow Annual |
| Indicator | Graph |
|---|---|
| Book Value Per Share Annual | |
| ROE Annual % | |
| ROCE Annual % | |
| Total Debt to Total Equity Annual | |
| EBDIT Annual Margin % |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| NIKHIL KISHORCHANDRA VORA | 6.41 | 89027229 | - | - |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| DAULAT NARIMAN MEDHORA | 30.02 | 89027215 | 0 | 4.97 |
| NARIMAN MEDHORA | 15.32 | 89027216 | 0 | 20.08 |
| FREDUN NARIMAN MEDHORA | 3.82 | 89027217 | 0 | 10.61 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| BANK OF INDIA | 1.6 | 89027220 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| NIKHIL KISHORCHANDRA VORA | 6.41 | 89027229 |
| ARUN KUMAR MUKHERJEE | 1.7 | 89027230 |
| HUF | 1.95 | 89027222 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Sep 22, 2023 | 0.7 | FINAL | Sep 22, 2023 | Equity Share |
| Sep 16, 2021 | 0.7 | FINAL | - | Equity Share |
| Sep 18, 2020 | 0.66 | FINAL | Sep 21, 2020 | Equity Share |
| Sep 16, 2019 | 0.65 | FINAL | - | Equity Share |
| Sep 18, 2018 | 0.6 | FINAL | - | Equity Share |
| Sep 20, 2017 | 0.6 | FINAL | - | Equity Share |
| Apr 11, 2016 | 0.6 | INTERIM | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| Jul 29, 2024 | Quarterly Results | - |
| May 07, 2024 | Audited Results & Final Dividend | - |
| Feb 14, 2024 | Quarterly Results | - |
| Dec 16, 2023 | Others | Inter alia, to consider a proposal for fund raising up to Rs.120 crores by way of further public offer, rights issue, debt issue, preferential issue or any other method. |
| Nov 08, 2023 | Quarterly Results | - |
| Jul 19, 2023 | Quarterly Results | - |
| May 24, 2023 | Audited Results & Final Dividend | - |
| Jan 27, 2023 | Quarterly Results | - |
| Nov 10, 2022 | Quarterly Results | - |
| Aug 27, 2022 | Preferential issue of shares | - |
| Aug 12, 2022 | Quarterly Results | - |
| May 16, 2022 | Audited Results & Final Dividend | - |
| Jan 28, 2022 | Quarterly Results | - |
| Nov 06, 2021 | Quarterly Results | - |
| Aug 10, 2021 | Quarterly Results | - |
| Jun 28, 2021 | Audited Results | - |
| Feb 12, 2021 | Quarterly Results | - |
| Nov 09, 2020 | Quarterly Results | - |
| Sep 15, 2020 | Quarterly Results | - |
| Jul 29, 2020 | Audited Results | - |
| Feb 12, 2020 | Quarterly Results | - |
| Nov 11, 2019 | Quarterly Results | - |
| Aug 13, 2019 | Quarterly Results | - |
| Jun 10, 2019 | Audited Results & Dividend | - |
| May 30, 2019 | Audited Results & Dividend | - |
| Feb 11, 2019 | Quarterly Results | - |
| Dec 05, 2018 | Others | Inter alia, to consider and approve To consider and approve the Postal Ballot Notice or Notice of the Extra-Ordinary General Meeting of the Shareholders of the Company as the Board will decide. |
| Nov 05, 2018 | Quarterly Results | - |
| Aug 14, 2018 | Quarterly Results & Others | - |
| Aug 01, 2018 | Preferential Issue of shares | - |
| Jun 18, 2018 | Audited Results & Final Dividend | (Revised) |
| May 24, 2018 | Others | - |
| Mar 28, 2018 | Others | - |
| Feb 12, 2018 | Quarterly Results | - |
| Jan 16, 2018 | Others | To consider and approve the allotment of 4,99,999 Equity shares. (Revised) |
| Nov 13, 2017 | Quarterly Results | - |
| Sep 22, 2017 | Others | - |
| Aug 11, 2017 | Quarterly Results | - |
| Jul 14, 2017 | Allotment of equity shares | Allotment of 5,72,735 Equity shares under the Preferential Issue to eligible investors. |
| May 30, 2017 | Audited Results & Dividend | - |
| May 05, 2017 | Others | Redemption of the Preference shares and issue of Equity shares under the preferential guidelines. |
| Mar 24, 2017 | Others | Consider and approve the matter of, obtaining Loan/Credit facility of upto 1 Crore 50 Lakhs from Indusind Bank for a period of 90 days/3 months. |
| Feb 24, 2017 | Others | To discuss, consider and approve the matter of the Increasing Authorised Capital of the Company. |
| Feb 13, 2017 | Quarterly Results | - |
| Jan 18, 2017 | Others | 1. To consider obtaining on lease a property for storage purposes for a period of 12 months. 2. To consider the matter of obtaining a Loan from Fredun Healthcare Private Limited. |
| Nov 09, 2016 | Quarterly Results & Others | To consider availing credit facility of Rs. 1,00,00,000 (One Crore) from Induslnd Bank (Bankers to the Company). |
| Oct 07, 2016 | Others | To consider obtaining on lease premises for office use. |
| Aug 11, 2016 | Quarterly Results | - |
| Jun 08, 2016 | Others | Approve and allot 8% Redeemable Non Convertible Cumulative Preference shares to the extent of Rs. 2.50 Crores as per the Resolution passed under Section 42,55,62. |
| May 30, 2016 | Audited Results | General Business Review General Discussion took place between the Board on the overall Business Activities of the Company. |
| Apr 27, 2016 | Others | To consider and approve the matter of issuing Redeemable Preference shares and to hold an Extra Ordinary General Meeting in this respect. |
| Mar 31, 2016 | Interim Dividend | To discuss, consider and approve the issue of Equity shares of the Company to the investors under the preferential Guidelines. |
| Ex-Date | Bonus Ratio | Record Date |
|---|
29 Jul 2024
Fredun Pharmaceuticals Ltd - 539730 - Outcome Of Board Meeting
Outcome of Board Meeting along with financial Results for the quarter ended 30th June, 2024
29 Jul 2024
Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for OUTCOME OF BOARD MEETING
Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, July 29, 2024 has inter-alia, considered, adopted and approved following items of business: 1. In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the Quarter Ended 30th June, 2024 along with the Limited Review Report as issued by M/s. R.H. Nisar & Co, Statutory Auditors of the Company; copies of which are attached hereunder; In furtherance to the intimation filed by the Company dated June 27, 2024; the trading window for trading in securities of the Company by insiders closed on July 01, 2024 till the end of 48 hours after the declaration of outcome of Board Meeting. The Board Meeting commenced at 04:00 p.m. and concluded at 07:15 p.m.
20 Jul 2024
Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Intimation for Prior Intimation For The Board Meeting Of The Company To Be Held On Monday, 29Th July, 2024.
Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2024 ,inter alia, to consider and approve Notice is hereby given pursuant to Reg 29 read with Regulation 33 of SEBI (LODR) Reg, 2015, that the meeting of the Board of Directors of Fredun Pharmaceuticals Limited is scheduled to be held on Monday, 29th July, 2024 inter alia, to consider and approve the following: 1. To discuss, consider and approve Unaudited Financial Results of the Company for the Quarter ended June 30, 2024. 2. Any other matter with the permission of the Chair. Further, in continuation of our intimation dated June 27, 2024 and pursuant to Company''s 'Code of Conduct' formed under the SEBI (PIT' ) Regulations, 2015 and amendments thereunder, the trading window for dealing in the securities of the Company has been closed from July 01, 2024 and it shall remain closed until forty-eight hours after the date of declaration of results for the Quarter ended June 30, 2024. The same has been circulated to the Directors, Key Managerial Personnel, Employees of the Company and their immediate relatives.
19 Jul 2024
Fredun Pharmaceuticals Ltd - 539730 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018
27 Jun 2024
Fredun Pharmaceuticals Ltd - 539730 - Closure of Trading Window
Closure of Trading Window
30 May 2024
Fredun Pharmaceuticals Ltd - 539730 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the F.Y. ended 31st March, 2024
10 May 2024
Fredun Pharmaceuticals Ltd - 539730 - Corporate Action-Board approves Dividend
Revision in Financial Results
10 May 2024
Fredun Pharmaceuticals Ltd - 539730 - Revised Financial Results For The Financial Year 2023-24
Revised Financial Resuls
10 May 2024
Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Revised Outcome - Board Meetig Dated 07.05.2024
Revised outcome for the Board Meeting Dated 07.05.2024 
